References
Zora Publications:
CERT in secondary prevention
Hilvo et al. 2019 Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. Eur Heart J. published online June 18, 2019. Link to the article
CERT and diabetes risk:
Hilvo et al. 2018 Ceramide stearic to palmitic acid ratio predicts incident diabetes. Diabetologia 2018; 61(6):1424–1434. Link to the article
Laaksonen et al. 2016 Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. European Heart Journal 2016; 37(25): 1967–1976. Link to the article
CERT in primary prevention:
Havulinna et al. 2016 Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort. Arterioscler Thromb Vasc Biol. 2016; 36: 2424–2430. Link to the article
CERT in secondary prevention:
Anroedh et al. 2018 Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. J. Lipid Res. 2018, 59(6). Link to the article
Cheng et al. 2015 Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study. Atherosclerosis 2015; 243(2):560-6. Link to the article
Tarasov et al. 2014 Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J. Clin. Endocrinol. Metab. 2014;99(1):E45-52. Link to the article
CERT analytical validation
Kauhanen et al. 2016 Development and validation of a high-throughput LC-MS/MS assay for routine measurement of molecular ceramides. Anal Bioanal Chem. 2016; 408(13): 3475-83. Link to the article
Ceramide publications by others:
Meeusen et al. 2018 Plasma Ceramides – A Novel Predictor of Major Adverse Cardiovascular Events After Coronary Angiography. ATVB 2018; 38:1933–1939. Link to the article
Carvalho et al. 2018 Plasma Ceramides as Prognostic Biomarkers and Their Arterial and Myocardial Tissue Correlates in Acute Myocardial Infarction JACC 2018, 3(2):163-175. Link to the article
Mantovani et al. 2018 Association between plasma ceramides and inducible myocardial ischemia in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy. Metabolism 2018, 85: 305-312. Link to the article
Peterson et al. 2018 Ceramide Remodeling and Risk of Cardiovascular Events and Mortality. J. Am. Heart Assoc. 2018, 3;7(10). Link to the article
Summers 2018 Could Ceramides Become the New Cholesterol. Cell Metabolism 2018, 27(2):276-280. Link to the article
Wang DD et al. 2017 Plasma Ceramides, Mediterranean Diet, and Incident Cardiovascular Disease in the PREDIMED Trial (Prevención con Dieta Mediterránea). Circulation 2017, 135(21):2028-2040. Link to the article
Chaurasia & Summers 2015 Ceramides – Lipotoxic Inducers of Metabolic Disorders. Trends Endocrinol. Metab. 2015, 26(10):538-50. Link to the article
Kasumov et al. 2015 Improved insulin sensitivity after exercise training is linked to reduced plasma C14:0 ceramide in obesity and type 2 diabetes. Obesity 2015; 23:1414-21. Link to the article
Chavez & Summers 2012 A ceramide-centric view of insulin resistance. Cell Metab. 2012, 15(5):585-94. Link to the article
Bikman & Summers 2011 Ceramides as modulators of cellular and whole-body metabolism. J. Clin. Invest. 2011, 121(11):4222-30. Link to the article
Holland & Summers 2008 Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev. 2008, 29(4):381-402. Link to the article